Back to Journals » ClinicoEconomics and Outcomes Research » Volume 8

Designing economic evaluations to facilitate optimal decisions: the need to avoid bias

Authors Lee KM, Coyle K, Coyle D

Received 21 November 2015

Accepted for publication 26 November 2015

Published 5 April 2016 Volume 2016:8 Pages 73—76

DOI https://doi.org/10.2147/CEOR.S101013

Checked for plagiarism Yes

Editor who approved publication: Professor Giorgio Lorenzo Colombo


Karen M Lee,1,3 Kathryn Coyle,2 Doug Coyle2,3

1Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada; 2Health Economics Research Group, Brunel University, Uxbridge, UK; 3School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON, Canada

Guertin et al1 argue in their article “Bias within economic evaluations” that if researchers
fail to incorporate the future availability of generics entrants for new patented drugs, the incremental cost-effectiveness ratio (ICER) will be overestimated.1 Before addressing the validity of this argument, it is first worthwhile to consider the nature of both bias and economic evaluation.

Read the original paper by Guertin et al


 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]